Medline (MDLN) Q4 FY25 earnings call

Medline concluded FY25 with robust sales growth and a strengthened financial position following its IPO, enabling continued strategic investments in automation, technology, and product innovation. The company successfully navigated significant tariff headwinds through mitigation efforts and pricing discipline, while also securing record new customer signings. Management remains confident in its resilient business model and long-term value creation, despite anticipating some moderation in healthcare utilization and ongoing tariff volatility.